BNR logo
BNR
Brenntag

Specialty Chemicals And Biopharma Expansion Will Unlock Long-Term Value

Published
25 Nov 24
Updated
20 Aug 25
AnalystConsensusTarget's Fair Value
€62.83
13.6% undervalued intrinsic discount
20 Aug
€54.26
Loading
1Y
-16.7%
7D
1.0%

Author's Valuation

€62.8

13.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates8

Shared on01 May 25
Fair value Decreased 15%

Read more

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on17 Apr 25
Fair value Decreased 0.95%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25
Fair value Decreased 4.81%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on26 Mar 25
Fair value Increased 0.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25
Fair value Decreased 0.051%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on12 Mar 25
Fair value Increased 20%

AnalystConsensusTarget has increased revenue growth from 2.6% to 3.8%.

Read more